Login
Rockwell Medical NASDAQ: RMTI
Rockwell Medical operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases
| Name | Rockwell Medical |
| Ticker | RMTI |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Kidney Failure |
|
Price
52W Low/High |
0.97
0.84 / 2.51 |
| Momentum | Sharp Down |
| Market cap | 91 M |
| 1Y Total Return |
-61.35%
Weak |
| 1Y Volatility |
77.77%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Rockwell Medical operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases
Details
| Ticker | RMTI |
| Name | Rockwell Medical |
| ISIN | US7743741024 |
| CUSIP | 774374102 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Kidney Failure |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 4/13/21
| Close Price | 0.97 |
| 52W Low/High | 0.84 / 2.51 |
| Market cap | 91 M |
| 1Y Total Return |
-61.35%
Weak |
| 1Y Volatility |
77.77%
High Risk |
| Beta | 2.19 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -49.7% |
| Cash from Op. / Cur. Liabilities | -2.32 |
| Diluted Earnings / Share | -0.41 |
| ROE | - |
| ROIC | -159.3% |
| Price / Revenue | 1.2 |
| Price / Book | 2.1 |
| Price / CF | -2.5 |
| Current Ratio | 5.4 |
| Cur.Liabilities / Tot.Liabilities | 0.3 |
| Financial Leverage | 0.70 |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
62
|
61
|
63
|
57
|
53
|
55
|
|
| Gross Profit |
3
|
3
|
-
|
4
|
7
|
9
|
|
| R&D |
7
|
7
|
7
|
6
|
6
|
5
|
|
| EBITDA |
-27
|
-31
|
-31
|
-25
|
-19
|
-14
|
|
| Operating Income |
-28
|
-35
|
-32
|
-26
|
-20
|
-15
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
76
|
61
|
53
|
51
|
-
|
-
|
|
| EPS exc. Extra |
-0.41
|
-0.56
|
-0.61
|
-0.51
|
-0.39
|
-0.29
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
78
|
44
|
53
|
59
|
83
|
88
|
|
| Cash, Eq & Invt ShortTerm |
59
|
26
|
34
|
33
|
58
|
71
|
|
| Total Current Assets |
69
|
37
|
47
|
49
|
79
|
85
|
|
| Total Non-Current Assets |
8
|
7
|
6
|
10
|
5
|
3
|
|
| Intangibles |
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Liabilities |
44
|
24
|
25
|
26
|
30
|
26
|
|
| Total Current Liabilities |
13
|
12
|
13
|
9
|
10
|
8
|
|
| Long Term Debt |
31
|
12
|
12
|
17
|
20
|
17
|
|
| Shareholder equity |
34
|
20
|
27
|
33
|
53
|
62
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-30
|
-27
|
-20
|
-21
|
-12
|
-13
|
|
| Depreciation |
2
|
3
|
1
|
1
|
1
|
1
|
|
| Cash from Investing |
3
|
-5
|
13
|
15
|
-2
|
-21
|
|
| Capex |
1
|
1
|
1
|
2
|
0
|
1
|
|
| Cash from Financing |
63
|
21
|
22
|
-2
|
0
|
0
|
|
| Stock Issued |
43
|
22
|
22
|
-2
|
0
|
3
|
|
| Debt (LT) Issued |
20
|
-1
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
-28
|
-28
|
-22
|
-29
|
-25
|
-21
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
5.4
|
3.0
|
3.5
|
5.3
|
7.7
|
10.5
|
|
| Financial Leverage D/E |
0.70
|
0.20
|
0.00
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-159.3%
|
-185.4%
|
-111.0%
|
-53.4%
|
-38.2%
|
-40.7%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available